{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:51:00Z","timestamp":1782280260973,"version":"3.54.5"},"reference-count":21,"publisher":"Wiley","license":[{"start":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T00:00:00Z","timestamp":1536710400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sarcoma"],"published-print":{"date-parts":[[2018,9,12]]},"abstract":"<jats:p><jats:italic>Objective<\/jats:italic>. To describe health care resource utilization and costs for patients with advanced soft tissue sarcoma (STS) in the United Kingdom (UK), Spain, Germany, and France. <jats:italic>Methods<\/jats:italic>. Physicians abstracted data for adult patients with a diagnosis of advanced STS (other than Kaposi\u2019s sarcoma or gastrointestinal stromal tumor) who received \u22651 lines of systemic therapy. Health care resource utilization related to advanced STS treatment was recorded; associated costs were estimated by applying unit costs. <jats:italic>Results<\/jats:italic>. A total of 130 physicians provided data for 807 patients (UK: 199; Spain: 203; Germany: 204; and France: 201). The site of care during active treatment varied based on differences in the health care systems of these four countries. Total mean per-patient health care cost in the UK was \u00a319,457; in Spain, \u20ac26,814; in Germany, \u20ac20,468; and in France, \u20ac24,368. Advanced STS-related systemic treatment costs were driven primarily by drug acquisition and administration costs. Treatment-related costs increased during later lines of therapy for all countries except France, where they decreased after first-line therapy. Pain control and antiemetics were the most common supportive care medications. <jats:italic>Conclusions<\/jats:italic>. This study provides real-world data on resource utilization and estimated costs in advanced STS and could inform policymakers about treatment burden.<\/jats:p>","DOI":"10.1155\/2018\/2020591","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T19:31:36Z","timestamp":1536780696000},"page":"1-13","source":"Crossref","is-referenced-by-count":6,"title":["Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France"],"prefix":"10.1155","volume":"2018","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-8634","authenticated-orcid":true,"given":"Daniel S.","family":"Mytelka","sequence":"first","affiliation":[{"name":"Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh P.","family":"Nagar","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"D\u2019yachkova","sequence":"additional","affiliation":[{"name":"Eli Lilly Gesellschaft m.b.H., Koelblgasse 8-10, 1030 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"La","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Kaye","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA 02452, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean D.","family":"Candrilli","sequence":"additional","affiliation":[{"name":"RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-8356","authenticated-orcid":true,"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[{"name":"Mannheim University Medical Center, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Lopez-Martin","sequence":"additional","affiliation":[{"name":"12 de Octubre University Hospital, Avenida de C\u00f3rdoba, s\/n, 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","year":"2013"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp415"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.09.011"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25538"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.7-4-348"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1159\/000362631"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23332"},{"issue":"3","key":"8","first-page":"iii102","volume":"25","year":"2014","journal-title":"Annals of Oncology"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.1.150"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12322"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/725305"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/481071"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.2362"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.2310"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5467057"},{"key":"25","year":"April 2016"},{"key":"28","year":"February 2016"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.77"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2533-4"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/813483"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/325189"}],"container-title":["Sarcoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/sarcoma\/2018\/2020591.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/sarcoma\/2018\/2020591.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/sarcoma\/2018\/2020591.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T19:31:38Z","timestamp":1536780698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/sarcoma\/2018\/2020591\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,12]]},"references-count":21,"alternative-id":["2020591","2020591"],"URL":"https:\/\/doi.org\/10.1155\/2018\/2020591","relation":{},"ISSN":["1357-714X","1369-1643"],"issn-type":[{"value":"1357-714X","type":"print"},{"value":"1369-1643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,12]]}}}